secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuphoria Therapeutics Inc. (NEUP)
CIK:        0001191070
Form:       8-K
Filed at:   2026-05-26T20:15:40+00:00
Accession:  0001213900-26-061028
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuphoria receives AUD 1.416M CTx CRC payment; eligible for ~4.65% of $460M milestones
--------------------------------------------------------------------------------

- Received AUD 1.416M from CTx CRC upon Pfizer's Phase III start in ER+/HER2- metastatic breast cancer.
- Believes eligible for ~4.65% of future milestone payments from CTXT, total estimated at USD 460M across all parties.
- Total distributions received from CTx CRC since 2016: AUD 3.52M.
- Historical licensing revenues include AUD 967K from MSD (PRMT5) in 2016 and multiple Pfizer-related payments.
- Company is a passive party and cannot determine whether future milestones will be achieved or payment amounts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/0001213900-26-061028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/ea0292160-8k_neuphoria.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-061028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer